Tonix Pharmaceuticals Completes Purchase of Facility to House Advanced Development Center (ADC) for Vaccine Programs
September 28, 2020 16:15 ET
|
Tonix Pharmaceuticals Holding Corp.
Facility Addresses the Shortage of Vaccine Production Capacity in the U.S. When Fully Operational the ADC Is Expected to be Capable of Manufacturing Clinical Trial Quality Vaccines, Including...
Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?
September 17, 2020 09:17 ET
|
Tonix Pharmaceuticals Holding Corp.
Webinar to be Moderated by Clive Cookson of the Financial Times on September 24, 2020 Panelists Include Representatives from IAVI, Merck and Tonix Pharmaceuticals NEW YORK, Sept. 17, 2020 (GLOBE...
Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19
September 15, 2020 09:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first...
Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia
September 03, 2020 09:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Interim Analysis Results from Ongoing Phase 3 RELIEF Study Expected in September; Topline Results Expected in Fourth Quarter 2020 Positive Outcomes in Both Trials Would Support Submission of NDA in...
Tonix Pharmaceuticals to Participate in Upcoming September Virtual Investor Conferences
August 27, 2020 07:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer...
Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
August 10, 2020 08:45 ET
|
Tonix Pharmaceuticals Holding Corp.
Preclinical data for TNX-1800, a Vaccine Candidate to Protect Against COVID-19, Expected in Fourth Quarter 2020 Interim Analysis Results for Phase 3 RELIEF Trial of TNX-102 SL for the...
Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder
August 06, 2020 09:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Food and...
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
August 04, 2020 09:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced that it has regained...
Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference
August 04, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical...
Tonix Pharmaceuticals to Participate in SNN Network Virtual Investor Conference
July 30, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer...